Our results suggest that Bn(6–14), containing the receptor-binding residues of bombesin, can substantially enhance the selective cytotoxicity of this mitochondria-disrupting peptide to bombesin receptor-overexpressing tumor cells and its anti-cancer efficacy in vivo without any obvious systemic toxicity. Here, GRP is linked to cancer.